Direct pharmacological assessment of clinically acquired models as a strategy to overcome resistance to tyrosine kinase inhibitors.
We have performed a study using cell lines established from biopsies of clinically resistant non-small cell lung cancers with the aim of discovering therapeutic strategies to overcome acquired resistance. Our results indicate that pharmacological assessment of tumor material might efficiently complement genetic profiling in the future path toward personalized medicine.
Massachusetts General Hospital; Center for Cancer Research; Boston, MA USA.
Cyril H
CH
Benes
cancer; drug resistance; personalized medicine; tyrosine kinase inhibitor